KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Accumulated Depreciation & Amortization: 2010-2024

  • Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization rose 15.57% to $2.3 billion in Q4 2024 from the same period last year, while for Dec 2024 it was $7.3 billion, marking a year-over-year increase of 18.71%. This contributed to the annual value of $482.9 million for FY2024, which is 14.70% up from last year.
  • Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $2.3 billion in Q4 2024, which was up 15.57% from $2.0 billion recorded in Q4 2023.
  • Over the past 5 years, Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $2.3 billion during Q4 2024, and registered a low of $1.1 billion during Q4 2020.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Accumulated Depreciation & Amortization value was $2.0 billion (recorded in 2023), while the average stood at $2.0 billion.
  • Data for Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization shows a peak YoY climbed of 23.61% (in 2021) over the last 5 years.
  • Regeneron Pharmaceuticals' Accumulated Depreciation & Amortization (Quarterly) stood at $1.1 billion in 2020, then increased by 23.61% to $1.4 billion in 2021, then rose by 19.39% to $1.7 billion in 2022, then climbed by 18.55% to $2.0 billion in 2023, then rose by 15.57% to $2.3 billion in 2024.
  • Its last three reported values are $2.3 billion in Q4 2024, $2.0 billion for Q4 2023, and $1.7 billion during Q4 2022.